NCT05884866View on ClinicalTrials.gov

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions

Chronic Renal FailureMechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte HomeostatisChronic Kidney Disease Stage 3Electrolyte and Fluid Balance Conditions

Interventions

DRUG

Dapagliflozin 10mg Tab

see arms

DRUG

Balcinrenone 50mg Capsule

see arms

DRUG

Balcinrenone 100mg Capsule

see arms

DRUG

Dapagliflozin matching Placebo

see arms

DRUG

Balcinrenone 50mg matching Placebo

see arms

DRUG

Balcinrenone 100mg matching Placebo

see arms

Trial Locations (2)

13005

TERMINATED

Assistance Publique-Hopitaux de Marseille (AP-HM), Marseille

90419

RECRUITING

Klinikum Nuernberg, Nuremberg

All Listed Sponsors

lead

Klinikum Nürnberg

OTHER